Session Information
Date: Tuesday, September 24, 2019
Session Title: Parkinsonisms and Parkinson-Plus
Session Time: 1:45pm-3:15pm
Location: Agora 3 West, Level 3
Objective: This study is aimed to investigate the clinical and therapeutic data of PD patients who have been evaluated at a dedicated-weekly Movement Disorders Clinic. Details of advanced therapies are summarized.
Background: In recent years advanced therapies have been used frequently in PD patients who do not respond well to medical treatments.
Method: Totally, 234 of 277 (84.4%) patients seen in a year, were PD patients in our movement disorders clinic. Duration of the disease, clinical characteristics, UPDRS scores and medications were recorded. Duration of > 5 years and unresponsiveness of the PD drugs were accepted as indication of advanced PD treatments. Clinical features of PD patients who were applied advanced therapies and their response were evaluated.
Results: 144 (61.5%) of the PD patients were male. Mean age of the patients was 67.9 (11.5) and their first symptom was tremor. Median disease duration was 5 years. The most frequently used drugs were Levodopa benserazid (52.1%), rasagiline (48.5 %) , levodopa-carbidopa-entacapone (36.7%) and pramipexole (27.8%). Number of PD patients requiring advanced therapies was 28 (12%). Among them, 18 device guided therapies were applied to 16 patients. Distribution of these patients were as apomorphine: 6 patients, levodopa carbidopa intestinal gel(LCIG): 7 patients, Deep Brain Stimulation (DBS): 5 patients. Apomorphine treatment was applied to 6 patients (3 intermittent injection, 3 pump). Apomorphine pump was failed in one patient. Apomorphine was switched to LCIG due to inadequate response (n=1) and due to injection reaction (n=1). LCIG was applied to 7 patients. There was no problem with the percutaneous endoscopic jejunostomy. All patients are still on LCIG treatment. Bilaterally subtalamic nucleus (STN) DBS were applied to totally 5 patients. There was no problem in the periodic follow up of these patients.
Conclusion: Totally over 10% of the PD patients had been followed in our clinic required advanced PD treatments. Advanced treatments resulted in major improvements with very few adverse events in 16 of our advanced group.
To cite this abstract in AMA style:
Y. Sucullu Karadag, D. Divanlıoglu, E. Kocabicak, N. Subutay Oztekin, D. Belen. Medical and Device-Guided Therapies and Deep Brain Stimulation in Parkinson’s disease: Experience of a Tertiary Centre from Turkey [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/medical-and-device-guided-therapies-and-deep-brain-stimulation-in-parkinsons-disease-experience-of-a-tertiary-centre-from-turkey/. Accessed May 13, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/medical-and-device-guided-therapies-and-deep-brain-stimulation-in-parkinsons-disease-experience-of-a-tertiary-centre-from-turkey/